Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

NEWS Press Release Media Report

Year:

Select

Press Release

07 November 2023

KN026 was Granted Breakthrough Therapy Designation by CDE KN026 is expected to become the first anti-HER2 treatment for second-line gastric cancer where HER2-targeted therapy has failed.
24 October 2023

Alphamab Oncology updated data from two studies of KN026 in combination with docetaxel for HER2-positive breast cancer at ESMO the results of two studies of HER2 bispecific antibody KN026 were presented at the European Society of Medical Oncology (ESMO) Annual Meeting
24 October 2023

Alphamab Oncology Announces New Data from Multiple Studies of KN046 with Lung Cancer and Thymic Carcinoma at ESMO the results of four studies of PD-L1/CTLA-4 bispecific antibody KN046 were presented at the European Society of Medical Oncology (ESMO) Annual Meeting
10 August 2023

Alphamab Oncology will update the research results of several core pipeline products at the 2023 ESMO Annual Meeting posters will be announce at the 2023 European Society for Medical Oncology (ESMO) Congress.
10 July 2023

The Results of Phase II Clinical Study of KN046 in NSCLC were published in European Journal of Cancer KN046 showed promising efficacy and favorable safety profile in advanced squamous and non-squamous NSCLC patients after failure of or intolerance to previous platinum-based chemotherapy.
07 June 2023

The Results of Phase I Clinical Study of KN046 were published in Journal for ImmunoTherapy of Cancer the phase I clinical research results of KN046 in advanced solid tumor
06 June 2023

Alphamab Oncology updated clinical research data for KN026 in Combination with KN046 in HER2-Positive Solid Tumors at the ASCO 2023 annual meeting The data released at ASCO includes a larger population of patients for efficacy analysis and a longer follow-up period, compared with results of AACR poster.
10 May 2023

Alphamab Oncology will present updated data on innovative bispecific antibody combination therapy at ASCO 2023 Efficacy and Safety of KN026 in combination with KN046 in Patients with Locally Advanced Unresectable or Metastatic HER2-positive Other Solid Tumors
09 May 2023

IND Application for Phase Ⅲ Registration Study of KN026 in Combination with Chemotherapy for the First-line Treatment of Breast Cancer Was Approved by CDE We will further explore the efficacy and safety of KN026 in combination with docetaxel through this registered clinical trial, in the hope of bringing more effective treatment options to patients with...
17 April 2023

Late-Breaking Research! Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023 KN052 has acceptable pharmacokinetics and safety, and its antitumor activity is significantly stronger than that of the two single-target control antibodies used alone and in combination.